NASDAQ · NMRA
Neumora Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NMRA: Nov 5, 2026
Neumora Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.19. The reported EPS for the same quarter last year was $-0.35.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.19 | $-0.17 | $-0.20 | 4 |
| Dec 2026 | $-0.16 | $-0.13 | $-0.18 | 4 |
| Mar 2027 | $-0.14 | $-0.10 | $-0.18 | 3 |
| Jun 2027 | $-0.15 | $-0.10 | $-0.18 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · RTTNews · Zacks · Fintel- The Motley Fool · Aug 31, 5:04 AM EDTJohnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.J&J's portfolio primarily includes small biotech and medtech companies.
- RTTNews · Aug 14, 9:46 AM EDTNeumora Q2 Loss Narrows, Advances CNS Pipeline; Names Joshua Pinto CEO(RTTNews) – Neumora Therapeutics, Inc. (NMRA), a clinical-stage biopharmaceutical company developing therapies for brain and centrally mediated diseases, reported financial results for the second quarter of 2026 and provided updates on its pipeline.
- RTTNews · Jul 31, 10:51 AM EDTWeekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals(RTTNews) – The healthcare sector delivered another eventful week, marked by major regulatory approvals, strategic partnerships, acquisitions, restructuring initiatives and significant clinical trial updates.
- RTTNews · Jul 28, 5:52 AM EDTNeumora Reports Positive Toxicology Data For NMRA-215; IND Planned For Q4 '26(RTTNews) – Neumora Therapeutics Inc. (NMRA), a clinical-stage biopharmaceutical company, on Monday released positive pre-clinical toxicology data for NMRA-215, an NLRP3 inhibitor developed for treating obesity and cardiometabolic disease.
- RTTNews · Jun 19, 5:09 AM EDTWeekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera(RTTNews) – This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts.
- Zacks · Jun 16, 10:13 AM EDTNeumora Stock Plunges 49% After Late-Stage Depression Drug FailureNMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals, leading to discontinuation of its development.
- RTTNews · Jun 15, 12:02 PM EDTNeumora Ends Phase 3 KOASTAL Study Of Navacaprant, To Lay Off 35% Of Workforce; Stock Plunges 50%(RTTNews) – Neumora Therapeutics Inc. (NMRA), a clinical-stage biopharmaceutical company, on Monday announced the discontinuation of the Phase 3 KOASTAL program evaluating Navacaprant for the treatment of major depressive disorder. Following the announcement, shares fell over
- Fintel · Apr 9, 3:52 PM EDTNeumora Therapeutics (NMRA) Price Target Increased by 19.25% to 9.33The average one-year price target for Neumora Therapeutics (NasdaqGS:NMRA) has been revised to $9.33 / share. This is an increase of 19.25% from the prior estimate of $7.82 dated March 25, 2026. The price target is an average of many targets provided by analys
- NASDAQ.com · Mar 27, 4:00 PM EDTPre-Market Earnings Report for March 30, 2026 : SGML, BCAX, NMRA, CBAT, PDSB, PAVMThe following companies are expected to report earnings prior to market open on 03/30/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Sigma Lithium Corporation (SGML)is reporting for the quarter ending December 31, 2025. The mining company's conse
- Fintel · Feb 17, 3:02 PM ESTWilliam Blair Upgrades Neumora Therapeutics (NMRA)Fintel reports that on February 17, 2026, William Blair upgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Market Perform to Outperform. Analyst Price Forecast Suggests 191.43% Upside
- Fintel · Jan 12, 11:52 AM ESTLeerink Partners Initiates Coverage of Neumora Therapeutics (NMRA) with Outperform RecommendationFintel reports that on January 12, 2026, Leerink Partners initiated coverage of Neumora Therapeutics (NasdaqGS:NMRA) with a Outperform recommendation. Analyst Price Forecast Suggests 321.17% Upside
- RTTNews · Jan 9, 7:53 AM ESTWeekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances(RTTNews) – The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Neumora Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.